Navigation Links
Targeted testing offers treatment hope for ovarian cancer patients
Date:5/31/2011

Women with ovarian cancer could be helped by a new test that identifies the specific type of tumour they have, a conference will hear this week.

Researchers at the University of Edinburgh hope this improved diagnosis will help doctors to personalise treatment programmes so that patients receive the most effective drugs.

The Edinburgh team worked with scientists from Ireland to identify six subgroups of the disease, each of which had a different genetic signature.

To do this, they analysed tissue samples from more than 350 ovarian cancer patients and compared this information with the patients' medical records.

The results show how genetic profiling of ovarian cancers might predict a person's response to drug treatments.

Researchers say the development may be particularly helpful for women with an aggressive form of ovarian cancer, which is typically caught late by current diagnostic tests.

This type of aggressive or 'high grade' cancer can respond well to a recently-developed drug that targets the blood supply of the cancer cells.

The team hopes that by identifying the women with this type of cancer at the earliest opportunity, they could use the drug more effectively and help to improve survival rates.

The findings will be presented at the American Society of Clinical Oncology (ASCO) conference, being held in Chicago this week.

Dr Charlie Gourley of the University of Edinburgh, who led the study, said: "This research shows that by conducting a detailed analysis of the genes of ovarian cancers we may be able to identify those patients who will respond well to new drug treatments. This could bring valuable improvements in survival rates for the disease and would help us to personalise a patient's care to ensure the greatest possible success."

Ovarian cancer is the fifth most common cancer in women, with around 6,800 women being diagnosed every year in the UK.

Of these, nearly two-thirds will not live beyond five years of their diagnosis.

Chemotherapy and surgery can be effective treatments, but women could have a greater chance of surviving the disease if it is identified earlier on.

The findings will be presented at ASCO on Saturday 4th June.


'/>"/>

Contact: Anna Borthwick
anna.borthwick@ed.ac.uk
44-131-651-4400
University of Edinburgh
Source:Eurekalert

Related medicine news :

1. Targeted delivery of losartan reduces liver inflammation and scarring
2. Gene-Targeted Cancer Fix Could Be a Breakthrough
3. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
4. Targeted agent blocked growth of deadly brain cancer in preclinical studies
5. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
6. New targeted therapy effective in treating advanced prostate cancer
7. Gene-Targeted Therapy Might Help Prevent Paralysis
8. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
9. Drug in new class of targeted therapies shows early promise against blood-related cancers
10. Women Smokers Targeted on World No Tobacco Day
11. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... 2016 , ... CURE Media Group , the nation’s ... today announced that Lynne Malestic, RN, of Eisenhower Lucy Curci Cancer Center in ... Oncology Nursing , which honors nurses who have dedicated their careers to helping ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, Inc. ... line of probiotics, Petbiotics ™, as they fondly call them. As animal ... groups networking for their non-profit organizations. Animal rescues across the nation face huge ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in ... efficacy of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... 2014. Each year, reproductive endocrinologists are required to report in vitro fertilization ... of professionals dedicated to the practice of assisted reproductive technologies in the United ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
(Date:4/27/2016)... 27, 2016 Transparency Market Research ... Market - Global Industry Analysis, Size, Share, Growth, Trends, ... the global skincare devices market was valued at US$ ... at a CAGR of 10.1% from 2015 to 2023 ... Browse the full Skincare Devices Market (Treatment Device - LED ...
Breaking Medicine Technology: